Lista de obras - Alberto Fabbri - Dominio Público Uruguay

A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement

artículo científico publicado en 2003

A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction

artículo científico publicado en 2011

A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase

artículo científico publicado en 2004

Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia.

artículo científico publicado en 2006

An unusual presentation of chronic B-cell lymphocytic leukaemia

artículo científico publicado en 2004

Atypical clinical presentation of visceral leishmaniasis in a patient with non-Hodgkin lymphoma

artículo científico publicado en 2014

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

artículo científico publicado en 2012

CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

artículo científico publicado en 2006

Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia

artículo científico publicado en 2014

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)

article

Concomitant t(4;11) and t(1;19) in a patient with biphenotypic acute leukemia

artículo científico publicado en 2007

Deletion 9q in a patient with concomitant myelodysplasia and non-Hodgkin lymphoma

artículo científico publicado en 2007

Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.

artículo científico publicado en 2014

Efficacy of rituximab in the treatment of refractory chronic lymphocytic leukemia patient with bone marrow aplasia

artículo científico publicado en 2002

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.

artículo científico publicado en 2015

Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2

artículo científico publicado en 2009

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

artículo científico publicado en 2008

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

artículo científico publicado en 2009

Hodgkin's lymphoma as Richter's transformation in chronic lymphocytic leukemia

artículo científico publicado en 2014

Hyperlipidemia in a myeloma patient after bortezomib treatment

artículo científico publicado en 2010

Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up

artículo científico publicado en 2012

Influence of psychological symptoms on home-recorded sleep-time masticatory muscle activity in healthy subjects

artículo científico publicado en 2011

Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.

artículo científico publicado en 2014

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.

artículo científico publicado en 2009

Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

artículo científico publicado en 2012

Low-dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

artículo científico publicado en 2014

Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma

artículo científico publicado en 2007

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders

artículo científico publicado en 2004

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

artículo científico publicado en 2008

Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib

scientific article published on 01 March 2007

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia

artículo científico publicado en 2013

Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination

artículo científico publicado en 2006

Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders

scientific article published on 19 November 2014

Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases

artículo científico publicado en 2006

Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma

artículo científico publicado en 2010

Predicting the clinical course of Hodgkin lymphoma

artículo científico publicado en 2010

Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT.

artículo científico publicado en 2006

Primary Nasopharyngeal Hodgkin Lymphoma

artículo científico publicado en 2015

Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma

artículo científico publicado en 2015

Rare lymphoid neoplasms coexpressing B- and T-cell antigens. The role of PAX-5 gene methylation in their pathogenesis

artículo científico publicado en 2009

Renal infarction due to polyarteritis nodosa in a patient with angioimmunoblastic T-cell lymphoma: a case report and a brief review of the literature

artículo científico publicado en 2012

Reply to 'Rituximab activity in CD20-positive multiple myeloma'

artículo científico publicado en 2007

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia

artículo científico publicado en 2011

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study

artículo científico publicado en 2010

Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.

artículo científico publicado en 2018

Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.

artículo científico publicado en 2014

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

artículo científico publicado en 2016

Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma

artículo científico publicado en 2010

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

artículo científico publicado en 2010

Treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma

artículo científico publicado en 2015

Trisomy 12 and t(14;22)(q32;q11) in a Patient with B-cell Chronic Lymphocytic Leukemia

scientific article published on 01 October 2004

Trisomy 13 in a patient with idiopathic myelofibrosis

artículo científico publicado en 2005

Trisomy 22 as sole cytogenetic abnormality in acute monoblastic leukemia (M5b)

artículo científico publicado en 2006

Unusual localizations of plasmacytoma

artículo científico publicado en 2011

Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2010

Lista de obras de Alberto Fabbri

A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement

A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction

A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase

Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia.

An unusual presentation of chronic B-cell lymphocytic leukaemia

Atypical clinical presentation of visceral leishmaniasis in a patient with non-Hodgkin lymphoma

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma

Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)

Concomitant t(4;11) and t(1;19) in a patient with biphenotypic acute leukemia

Deletion 9q in a patient with concomitant myelodysplasia and non-Hodgkin lymphoma

Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas.

Efficacy of rituximab in the treatment of refractory chronic lymphocytic leukemia patient with bone marrow aplasia

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.

Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

Hodgkin's lymphoma as Richter's transformation in chronic lymphocytic leukemia

Hyperlipidemia in a myeloma patient after bortezomib treatment

Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up

Influence of psychological symptoms on home-recorded sleep-time masticatory muscle activity in healthy subjects

Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.

Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

Low-dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia

Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination

Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders

Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases

Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma

Predicting the clinical course of Hodgkin lymphoma

Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT.

Primary Nasopharyngeal Hodgkin Lymphoma

Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma

Rare lymphoid neoplasms coexpressing B- and T-cell antigens. The role of PAX-5 gene methylation in their pathogenesis

Renal infarction due to polyarteritis nodosa in a patient with angioimmunoblastic T-cell lymphoma: a case report and a brief review of the literature

Reply to 'Rituximab activity in CD20-positive multiple myeloma'

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia

Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study

Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.

Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

Treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma

Trisomy 12 and t(14;22)(q32;q11) in a Patient with B-cell Chronic Lymphocytic Leukemia

Trisomy 13 in a patient with idiopathic myelofibrosis

Trisomy 22 as sole cytogenetic abnormality in acute monoblastic leukemia (M5b)

Unusual localizations of plasmacytoma

Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma